Business Description
Aprea Therapeutics Inc
NAICS : 325412
SIC : 2836
ISIN : US03836J2015
Total Employee Number:
8Description
Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.87 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 55.2 | |||||
3-Year EPS without NRI Growth Rate | 55.9 | |||||
3-Year FCF Growth Rate | 49.3 | |||||
3-Year Book Growth Rate | -46 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 25.37 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 110.93 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 41.18 | |||||
9-Day RSI | 41.17 | |||||
14-Day RSI | 42.66 | |||||
3-1 Month Momentum % | -22.02 | |||||
6-1 Month Momentum % | -12.38 | |||||
12-1 Month Momentum % | -53.31 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 8.92 | |||||
Quick Ratio | 8.92 | |||||
Cash Ratio | 8.77 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -45.6 | |||||
Shareholder Yield % | -456.26 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -63.65 | |||||
ROA % | -51.8 | |||||
ROIC % | -1358.32 | |||||
3-Year ROIIC % | -9355.81 | |||||
ROC (Joel Greenblatt) % | -19291.41 | |||||
ROCE % | -64.09 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 0.2 | |||||
Price-to-Tangible-Book | 0.2 | |||||
EV-to-EBIT | 3 | |||||
EV-to-EBITDA | 3 | |||||
EV-to-Forward-Revenue | 1.45 | |||||
EV-to-FCF | 3.13 | |||||
| Price-to-Net-Current-Asset-Value | 0.21 | |||||
| Price-to-Net-Cash | 0.21 | |||||
Earnings Yield (Greenblatt) % | 33.33 | |||||
FCF Yield % | -136.81 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:APRE
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Aprea Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.54 | ||
| Beta | 1.2547 | ||
| 3-Year Sharpe Ratio | -0.37 | ||
| 3-Year Sortino Ratio | -0.56 | ||
| Volatility % | 43.78 | ||
| 14-Day RSI | 42.66 | ||
| 14-Day ATR ($) | 0.067682 | ||
| 20-Day SMA ($) | 0.755773 | ||
| 12-1 Month Momentum % | -53.31 | ||
| 52-Week Range ($) | 0.548 - 2.22 | ||
| Shares Outstanding (Mil) | 12.38 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Aprea Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Aprea Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-12 | In 116 days | ||
| Second quarter earnings results for 2026 | 2026-08-12 | In 24 days | ||
| General meeting for 2026 | 2026-06-16 09:00 | 0.70 (+1.10%) | ||
| First quarter earnings results for 2026 | 2026-05-13 | 0.90 (-6.86%) | ||
| Annual report for 2025 | 2026-03-16 | 0.74 (-4.37%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-16 | 0.74 (-4.37%) | ||
| Oppenheimer 36th Annual Healthcare Life Sciences Conference | 2026-02-26 08:40 | 0.88 (+12.18%) | ||
| Third quarter earnings results for 2025 | 2025-11-12 | 1.32 (+3.94%) | ||
| H.C. Wainwright 27th Annual Global Investment Conference | 2025-09-09 15:30 | 1.61 (+3.87%) | ||
| Second quarter earnings results for 2025 | 2025-08-12 | 1.69 (-3.43%) |
Show
Entries
Aprea Therapeutics Inc Frequently Asked Questions
What is Aprea Therapeutics Inc(APRE)'s stock price today?
The current price of APRE is $0.71. The 52 week high of APRE is $2.22 and 52 week low is $0.55.
When is next earnings date of Aprea Therapeutics Inc(APRE)?
The next earnings date of Aprea Therapeutics Inc(APRE) is 2026-08-12 Est..
Does Aprea Therapeutics Inc(APRE) pay dividends? If so, how much?
Aprea Therapeutics Inc(APRE) does not pay dividend.
Guru Commentaries on NAS:APRE
No articles.
Press Release
| Subject | Date | ||
|---|---|---|---|
| Thinking about buying stock in Verastem, Corvus Pharmaceuticals, Aprea Therapeutics, Spectrum Pharmaceuticals, or SmileDirectClub? | 2021-09-20 |
Articles on Aprea Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers